Jeremy Green
Founder and Portfolio Manager @ Redmile Group
Paris, France
Jeremy Green is a Series B investor at Redmile Group in Paris focused on Health Care and Biotechnology. He is a founder and portfolio manager at Redmile Group. He completed his education at the University of Oxford.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Jeremy Green invests in
Stages Jeremy Green invests in
Countries Jeremy Green invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (100%)
- Biotechnology 1 (100%)
- Pharmaceutical 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading Life Sciences Venture Capital groups and supported by a comprehensive intellectualproperty portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families.Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is leading the development within this emerging therapeutic space. | $45.2M / Series B / Sep 02, 2018 |
Co-Investors
About Redmile Group
Redmile Group is a healthcare investment organization that makes venture, growth, and crossover investing across healthcare.
Redmile Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Robert Faulkner
Managing Director
|
|||
Gerard van Hamel Platerink
Managing Director
|
|||
|
Jeremy Green
Founder and Portfolio Manager
|
|||
|
Mike Lee
Managing Director/Co-Founder
|
|||
Ming Fang
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jeremy Green invest in?
Jeremy Green invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jeremy Green?
Public channels for Jeremy Green include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jeremy Green last invest?
The most recent investment recorded for Jeremy Green closed in Sep 2018. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
